JAVELIN Bladder 100 Long-Term Data: Patients With Histological Subtypes, Low Tumor Burden

Petros Grivas, MD, PhD, of Fred Hutchinson Cancer Center, offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations: those with with histological subtypes and those with low tumor burden.

View his previous comments on Bladder Cancer Roundup: Enfortumab Vedotin, Nivolumab, and More.